Bolton Relay胸主动脉腔内修复关键试验的初期与中期结果
该前瞻性、非随机、多中心美国IDE研究显示,Relay胸主动脉支架治疗胸主动脉病变的30天主要不良事件率显著低于开放手术组(20.3% vs 48.3%,P<.001),5年免于动脉瘤相关死亡率两组相似(91.3% vs 89.4%,P=.406),器械相关并发症率低。
要点
- TEVAR组30天主要不良事件率显著低于手术组(20.3% vs 48.3%,P<.001)。
- 5年免于动脉瘤相关死亡率两组相似(91.3% vs 89.4%,P=.406)。
- 新型Relay Plus输送系统亚组主要不良事件率更低(15.8% vs 35.8%,P=.035)。
核心结论
- Relay胸主动脉支架与开放手术相比安全有效,5年内器械耐久性良好且器械相关并发症率低。
主要发现
- 支架成功输送并释放129/133例(97.0%)。
- 30天死亡率TEVAR组5.3% vs 手术组10.0%(P=.230),主要不良事件率20.3% vs 48.3%(P<.001),主要因呼吸衰竭(5.5% vs 21.6%,P=.007)和操作出血更少。
- 5年免于动脉瘤相关死亡率91.3% vs 89.4%(P=.406),全因死亡率57.1% vs 50.2%(P=.289),免于主要不良事件率65.7% vs 44.7%(P=.001)。
- 6例(4.5%)发生核心实验室报告的I型或III型内漏,10例(7.5%)接受二次手术,其中7例纠正内漏、1例手术转换;3例(2.3%)支架移位,2例(1.5%)线框断裂;113例(85.0%)动脉瘤囊缩小或稳定;无破裂或支架闭塞。
- Relay Plus输送系统亚组38例主要不良事件率15.8% vs 35.8%(P=.035),围术期卒中2.6% vs 12.6%(P=.108)。
临床怎么用
- 对于适合TEVAR的胸主动脉病变,Relay支架可降低30天主要不良事件风险,尤其呼吸衰竭和操作出血,且5年耐久性良好。
- 新型Relay Plus输送系统可能进一步降低主要不良事件和围术期卒中风险,但卒中差异未达统计学意义。
局限性
- 研究为非随机设计,手术对照组为前瞻性和回顾性混合入组,可能存在选择偏倚。
- 持续准入阶段样本量较小(13例),Relay Plus亚组仅38例,部分比较统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the initial and midterm results of the Bolton Relay Thoracic Stent Graft for the endovascular treatment of thoracic aortic lesions [thoracic endovascular aortic repair (TEVAR)]. METHODS: The Bolton Relay Thoracic Aortic Endovascular Pivotal Trial was a prospective, nonrandomized, multicenter, U.S. Investigational Device Exemption study conducted at 27 U.S. investigational sites. One hundred twenty TEVAR subjects were treated with the Relay device between January 2007 and May 2010, with 13 patients enrolled during the continued access phase through September 2012. TEVAR outcomes were compared with a prospectively and retrospectively enrolled surgical cohort consisting of 60 patients enrolled under similar inclusion/exclusion criteria. Follow-up examinations were prescribed at 1 month, 6 months, and yearly thereafter for 5 years. Major adverse events (MAEs) included stroke, paralysis/paraplegia, myocardial infarction, procedural bleeding, respiratory failure, renal failure, wound healing complications, and aneurysm-related mortality. RESULTS: Stent grafts were successfully delivered and deployed in 129 of 133 patients (97.0%). At 30 days, a lower rate of mortality was observed in the TEVAR arm (5.3% vs 10.0%; P = .230), and TEVAR was associated with a significantly lower rate of MAEs (20.3% vs 48.3%; P < .001), primarily driven by a lower frequency of respiratory failure in the cohort (5.5% vs 21.6%; P = .007) and procedural bleeding. Freedom from aneurysm-related mortality through 5 years was similar at 91.3% for the TEVAR cohort and 89.4% for the surgical cohort (P = .406); with 5-year freedom from all-cause mortality at 57.1% and 50.2% (P = .289), respectively. Freedom from MAEs through 5 years was significantly higher in the TEVAR cohort (65.7% vs 44.7%; P = .001). Six TEVAR patients (4.5%) experienced core laboratory-reported type I or III endoleaks, and secondary procedures were performed in 10 patients (7.5%), with seven procedures to correct endoleak and one surgical conversion. Endograft migration occurred in three patients (2.3%) and wireform fractures were assessed in two patients (1.5%). Aneurysm sac size decreased or remained stable in 113 patients (85.0%) over 5-year follow-up. There were no instances of rupture or endograft occlusion. A 38-subject subset treated with the newer Relay Plus Delivery System had a significantly reduced MAE rate (15.8% vs 35.8%; P = .035), and fewer perioperative strokes (2.6% vs 12.6%; P = .108). CONCLUSIONS: Data from the Relay TEVAR clinical trial demonstrate safety and effectiveness of the Relay device compared with surgical controls, indicating continued device durability with a low rate of device-related complications through 5 years.
引用
- Farber MA, Lee WA, Szeto WY, et al. Initial and midterm results of the Bolton Relay Thoracic Aortic Endovascular Pivotal Trial. J Vasc Surg. 2017. PMID: 28527926. doi:10.1016/j.jvs.2016.11.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。